BUZZ - Kodiak Sciences shares rise as its eye disease drug meets late-stage clinical trial goals

Latest Updates

September 28 - ** Drugmaker Kodiak Sciences (KOD.O) shares soared 141.1% to $78, reaching their highest level in over four years

** If the rally holds, the stock will post its biggest single-day gain on record

** The company stated its experimental drugs Zenkuda and tabirafusp-ted met primary goals in late-stage clinical trials for patients with wet age-related macular degeneration

** Both medicines showed vision improvement at the one-year mark that was no worse than the comparator drug aflibercept

** Wet age-related macular degeneration causes abnormal blood vessel leakage beneath the retina, potentially leading to central vision loss

** Approximately 54% of Zenkuda patients achieved a 6-month dosing interval, which could reduce the required number of eye injections

** The overall safety profile for both drugs was consistent with aflibercept; Kodiak plans further analysis to determine which patients may benefit most from tabirafusp-ted

** The company plans to seek U.S. approval for Zenkuda in the fourth quarter of 2026, based on five successful late-stage clinical trials for three retinal diseases

**Including this session, KOD is up 174.4% so far this year

(To assist non-English speakers, Reuters has automated translation of its reports into several other languages. As automated translations may contain errors or lack necessary context, Reuters does not guarantee the accuracy of translated texts, which are provided for reader convenience only. Reuters accepts no responsibility for any damages or losses incurred from the use of automated translation functions.)